Navigation Links
Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
Date:11/28/2012

lecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, successful commercialization and marketing of Zertane™ and the combination drug in Korea, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact: Rick Giles, Investor Relations, Ampio Pharmaceuticals, Inc. 720-437-6500

 

 

 


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
2. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
3. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
4. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
7. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
8. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
10. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
11. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , ... July 07, 2015 , ... CSM, a leading ... as Vice President of Finance. Morse has an extensive background in financial management and ... the CSM team. In his new role, Morse will oversee all financial areas of ...
(Date:7/6/2015)... UK (PRWEB) , ... July 06, 2015 , ... ... other medical fields holds potential to reveal how blood flows in the brain ... damage to the brain. , A new article published in the journal ...
(Date:7/6/2015)... , July 6, 2015  Approximately 1% of ... integrated into their chromosomes. These individuals are three times ... study published in one of the nation,s leading medical ... Medicine in Canada.  Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... herpesvirus 6 (HHV-6) causes roseola (also known as "sixth ...
(Date:7/6/2015)... 2015 Research and ... of the "Biotechnology for the Non-Biotechnologist" ... the Non-Biotechnologist, ideal for non-Scientists and Scientists needing ... potential of biotechnology. Ideal for Non-Scientists ... principles, techniques, and potential of biotechnology ...
Breaking Biology Technology:CSM Appoints Michael Morse as Vice President of Finance 2Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 2Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 3Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3
... Amnis Corporation and Gene Company, Ltd.,announced today ... Company,will sell and service the Amnis ImageStream(R) system ... Hong Kong, Shanghai,Beijing and Guangzhou now have access ... extremely pleased to have begun what we expect ...
... and Company) (NYSE: BDX ), a global medical technology company,announced ... Bank of America 2008 Healthcare Conference ... Bernstein 24th Annual Strategic Decisions Conference 2008 ... A live webcast of BD,s presentations can be accessed from the ...
... May 7 /PRNewswire-FirstCall/ Varian, Inc. (NasdaqGS:,VARI) announced that ... Glover,as a new director. Glover is the seventh ... appointed for a term expiring at the annual ... is Senior Vice President, Operations and Chief Financial ...
Cached Biology Technology:Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China 2James T. Glover Appointed to Board of Directors of Varian, Inc. 2
(Date:6/25/2015)... 2015  Imagine a tool specifically designed to help ... life. That,s exactly what USANA,s True Health Assessment ... portable health program provides a personalized approached to measuring ... your lifestyle and nutrition. At the ... night, USANA,s THA was honored with the Industry Innovation ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Sharp has selected ... secure authentication for its latest flagship smartphone device, ... than 200 million shipments of its fingerprint ID ... Synaptics, strength, scalability and leadership in the biometrics ...
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... in behaviour among the population have accelerated the recent decline ... in Science shows how there has been an almost 50 ... researchers attribute to people delaying when they first have sex ... fell most steeply at young ages, with a drop in ...
... one of the oldest healing remedies known to medicine, ... A review article in the most recent issue of ... the data. , Scientists performed 22 trials involving 2,062 ... 16 trials that were performed on experimental animals. Honey ...
... created in this cool movie , ,Scientists ... created polymer nanotubes that are unusually long (about 1 centimeter) ... Described in a new paper in Proceedings of the National ... as channels for tiny volumes of chemicals in nanofluidic reactor ...
Cached Biology News:HIV decline in Zimbabwe linked to behavioural change 2Stable polymer nanotubes may have a biotech future 2
Umbilical cord blood mesenchymal stem cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Biology Products: